论文部分内容阅读
用孕激素治疗复发和/或转移的子宫内膜腺癌失败后,阿霉素是最有效的单一制剂。在体外用人肿瘤克隆测定法,估价标准抗癌药对人类新鲜子宫内膜癌的抗癌效能提示:阿霉素、顺铂和长春花碱是试验中最有效的三种制剂。作者对用这三种制剂治疗的晚期和/成复发病人进行了Ⅱ阶段研究。研究对象为肿瘤复发或FIGOⅢ、Ⅳ期的病人,病理诊断为子宫内膜腺癌或腺鳞癌,既往未用过细胞毒类化疗药。化疗前,造血功能良好,肝肾功能正常,无心肌梗死或充血性心衰病史。骨髓储备良好的病人,首次剂量是:阿霉素30mg/m~2、顺铂50mg/m~2、长春花碱0.2mg/m~2,均在第一天静注。骨髓贮备不良的病人,首次剂量是:阿霉素20
Doxorubicin is the most effective single agent after failure of progestin to treat recurrent and / or metastatic endometrial adenocarcinoma. In vitro use of human tumor clonality assay to assess the anticancer efficacy of standard anti-cancer drugs on human fresh endometrial cancer Tip: Adriamycin, cisplatin and vinblastine are the three most effective agents in the trial. The authors conducted phase II studies of patients with advanced and / or recurrent disease treated with these three agents. The subjects were tumor recurrence or FIGO Ⅲ, Ⅳ patients, the pathological diagnosis of endometrial adenocarcinoma or adenosquamous carcinoma, previously not used cytotoxic chemotherapy drugs. Before chemotherapy, hematopoietic function is good, liver and kidney function is normal, no history of myocardial infarction or congestive heart failure. Patients with good bone marrow reserve, the first dose is: doxorubicin 30mg / m ~ 2, cisplatin 50mg / m ~ 2, vinblastine 0.2mg / m ~ 2, were intravenous injection on the first day. Patients with poor bone marrow reserve, the first dose is: doxorubicin 20